Clinical trial
Baltic Post-marketing Program of PEGASYS (Peg Interferon Alpha-2a 40KD) in Patients With HBeAg-positive and HBeAg-negative Chronic Hepatitis B
NCT00436163 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Baltic Post-marketing Program of PEGASYS (Peg Interferon Alpha-2a 40KD) in Patients With HBeAg-positive and HBeAg-negative Chronic Hepatitis B
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- March 31, 2007
- Completion date
- May 31, 2010
- Enrollment
- 39 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.